Cargando…
Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy
Despite recent advances, the efficacy of androgen/androgen receptor (AR)-targeted therapy remains limited for many patients with metastatic prostate cancer. This is in part because prostate cancers adaptively switch to the androgen/AR-independent pathway for survival and growth, thereby conferring...
Autores principales: | Geng, Hao, Xue, Changhui, Mendonca, Janet, Sun, Xiao-Xin, Liu, Qiong, Reardon, Patrick N., Chen, Yingxiao, Qian, Kendrick, Hua, Vivian, Chen, Alice, Pan, Freddy, Yuan, Julia, Dang, Sang, Beer, Tomasz M., Dai, Mu-Shui, Kachhap, Sushant K., Qian, David Z. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255907/ https://www.ncbi.nlm.nih.gov/pubmed/30478344 http://dx.doi.org/10.1038/s41467-018-07411-7 |
Ejemplares similares
-
Publisher Correction: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy
por: Geng, Hao, et al.
Publicado: (2019) -
HIF1 and ID1 Interplay Confers Adaptive Survival to HIF1α-Inhibition
por: Geng, Hao, et al.
Publicado: (2021) -
Racial Differences in Androgen Receptor (AR) and AR Splice Variants (AR-SVs) Expression in Treatment-Naïve Androgen-Dependent Prostate Cancer
por: Khan, Farhan, et al.
Publicado: (2023) -
Diverse roles of androgen receptor (AR) domains in AR-mediated signaling
por: Claessens, Frank, et al.
Publicado: (2008) -
Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer
por: Narayanan, Ramesh
Publicado: (2020)